Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear
fanfilcon A (test)
+ enfilcon A (control)
Maladies oculaires
+ Myopie
+ Erreurs de Réfraction
Étude thérapeutique
Résumé
Date de début de l'étude : 21 septembre 2015
Date à laquelle le premier participant a commencé l'étude.Subjects will be randomized into the study contact lenses in a two to one (2:1) ratio of fanfilcon A lens (test) to enfilcon A lens (control). This should result in a study population of approximately 60 test subjects and 30 control subjects.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.92 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.À partir de 18 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Inclusion Criteria: * Be at least 18 years of age as of the date of evaluation for the study. * Have: * Read the Informed Consent * Been given an explanation of the Informed Consent * Indicated understanding of the Informed Consent * Signed the Informed Consent document. * Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments. * Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses at least 5 days per week for at least 8 hours per day for at least one month prior to participation in the study. * Possess or obtain prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses. * Be in good general health, based on his/her knowledge. * Require spectacle lens powers between -0.50 and -8.00 diopters sphere with no more than 1.50 diopter of refractive astigmatism and be willing to wear contact lenses in both eyes. * Have manifest refraction Snellen visual acuities (VA) equal to or better than20/25 in each eye. * To be eligible for lens dispensing, the subject must achieve 20/30 VA or better in each eye with the study lens and the investigator must judge the fit as acceptable or optimal. Exclusion Criteria: * Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes for the duration of the study. Note: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis. * Poor personal hygiene. * Any active participation in another clinical trial during this trial or within 30 days prior to this study. * To the best of the subject's knowledge, she is currently pregnant, is lactating or is planning a pregnancy within the next 3 months. * A member, relative or household member of the investigator or of the investigational office staff. * Has a known sensitivity to the ingredients used in the Multi-Purpose Disinfection Lens Care System (MPS) approved for use in the study and is unable or unwilling to use the alternate care system. * Previous refractive surgery; or current or previous orthokeratology treatment. * Is aphakic or pseudophakic. * Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, keratoconus or uncontrolled diabetes. * The need for topical ocular medications or any systemic medication which might interfere with contact lens wear or require the lenses to be removed during the day. * The presence of clinically significant (grade 2, 3 or 4) anterior segment abnormalities; or the presence of any inflammations such as iritis; or any infection of the eye, lids, or associated structures. * A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, iritis, bacterial or fungal infections. * A history of papillary conjunctivitis that has interfered with contact lens wear. * Slit lamp findings that would contraindicate contact lens wear, including but not limited to: * Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining \> Grade 2 * Pterygium * Corneal scars within the visual axis * Neovascularization or ghost vessels \> 1.0 mm in from the limbus * Giant papillary conjunctivitis (GPC) of \> Grade 2 * Anterior uveitis or iritis * Seborrheic eczema, seborrheic conjunctivitis or blepharitis
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.2 groupes d'intervention sont désignés dans cette étude
Cette étude ne comporte pas de groupe placebo.
Groupes de traitement
Groupe I
ExpérimentalGroupe II
Comparateur actifObjectifs de l'étude
Objectifs principaux
Objectifs secondaires
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 6 sites
Mark Nakano, O.D.
Torrance, United StatesAdvanced Family Eye Care
Denver, United StatesQuinn, Foster & Associates
Athens, United States